Regeneron Pharmaceuticals Inc. said on Thursday the company’s experimental treatment for a very rare genetic bone disorder showed a nearly 90 percent reduction in new lesions compared to placebo, in a mid-stage study.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2020-01-09 07:36:192020-01-09 07:36:19Regeneron’s bone disorder drug reduces lesions in mid-stage study
